Supercross star won a championship in 2022, and is 'off to a great start' in '23; will this be his victory lap?
• Each has multiple championships in their given sports.Tomac rides at Snapdragon Stadium on Friday seeking a second straight and third overall Monster Energy Supercross championship. The Yamaha rider is also the reigning and five-time champion of the outdoor AMA Motocross Series.There had been speculation that 2022 would be Tomac’s final season. Then he won the championship and signed a one-year extension with Yamaha. But the deal does not include the 2023 outdoor season.
Then, several thoughts later, Tomac adds: “I’m very healthy, I’ve missed only two starts while racing at the highest level … and I’m off to a great start.” Tomac now has 45 career Supercross wins, which is fourth on the all-time list. Jeremy McGrath’s 72 wins may never be eclipsed. But James Stewart is second with 50 career wins and Ricky Carmichael is third with 48. A repeat of his seven-win, 2022 campaign would place Tomac second on the all-time list.
Although Tomac has won two of the past three championships, the last rider to win back-to-back titles was Ryan Dungey, who three-peated from 2015-2017.“Because Oakland was postponed last week , this is Round 2 of this season,” said Tomac. “We won’t know what this season looks like until after the third or fourth races. I’m not looking beyond that.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tom Hanks says his ideal ‘last meal’ would include the famous ‘Tom Cruise cake’Tom Hanks wants the cake Tom Cruise sends out during the holidays to be one of the last things he eats before he dies.
Read more »
Giants legends see Eli Manning in Daniel Jones as they endorse long-term dealJones is finishing up the four-year contract he signed after the Giants made him the No. 6-overall pick in the 2019 draft.
Read more »
FDA rejects Eli Lilly's proposed Alzheimer's treatment, says more data neededThe setback could delay a potential commercial introduction of the highly anticipated drug by at least several months, if the Food and Drug Administration...
Read more »
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drugEli Lilly and Co on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.
Read more »
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug(Reuters) -Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year. Lilly said the FDA had sent it a complete response letter for donanemab, an antibody designed to remove amyloid protein plaques from the brains of people with early Alzheimer's. Such letters typically outline concerns and conditions that must be addressed to gain U.S. approval. The FDA had issued the letter 'due to the limited number of patients with at least 12 months of drug exposure data provided in the submission,' Eli Lilly said.
Read more »
Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analystsThe U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
Read more »